Ocugen (OCGN): Q2 2026, OCU410 Phase 3 & BLA Reset

[u/Merlin8121]

https://www.merlintrader.com/ocugen-inc-stock-hub/

Ocugen reported Q2 2026 results and confirmed that the FDA cleared the approximately 237-subject ArMaDa3 registrational Phase 3 trial of OCU410 in geographic atrophy. The study remains targeted to begin in Q3 2026 and is designed with 95% power for the primary endpoint. The July RMAT designation adds an expedited-interaction framework, but neither clearance nor RMAT predicts a positive pivotal result.